Abstract
Illness-related absenteeism reduces firms’ output, an effect referred to as indirect cost (IC) and often included in cost-of-illness or cost-effectiveness (of health technologies) studies. The companies may foresee this effect and modify hiring or contracting policies. We present a model allowing the estimation of IC with such adjustments. We show that the risk of illness does not change the general shape and properties of the (expected) marginal productivity function. We apply our model to several illustrative examples and show that firm’s adjustments impact IC in an ambiguous way, depending on detailed company/market characteristics: in some cases the company reduces the employment (further increasing IC), in another—the opposite happens. Contrary to previous findings, teamwork and shortfall penalties may reduce IC in some settings. Our analysis highlights that IC should be split into the result of companies preparing for and actually experiencing sick leaves.
Similar content being viewed by others
Notes
This assumption approximately holds, e.g., in Poland, where the employer pays the salary for the first 33 days of the illness, and then the public insurer takes over (the employee gets 80% of a regular wage). Similar model is used in Germany, where the employer pays full salary for at least first 6 weeks of illness, then the insurer pays 70% of salary. In Sweden, employer covers sick-leaves for the first 2 weeks of illness.
References
Arnold, D., & de Pinto, M. (2014). Sickness absence, presenteeism and work-related characteristics: Conference paper. Conference: Beiträge zur Jahrestagung des Vereins für Socialpolitik 2015: Ökonomische Entwicklung—Theorie und Politik—Session: Labor-Empirical Studies 5, No G16-V1.
Audrey, S., & Procter, S. (2015). Employers’ views of promoting walking to work: A qualitative study. International Journal of Behavioral Nutrition and Physical Activity. doi:10.1186/s12,966-015-0174-8.
Berger, M., Murray, J., Xu, J., & Pauly, M. (2001). Alternative valuations of work loss and productivity. Journal of Occupational and Environmental Medicine, 43, 18–24.
Brouwer, W., van Exel, N., Baltussen, R., & Rutten, F. (2006). A dollar is a dollar is a dollar—Or is it? Value in Health, 9, 341–347.
Bryson, A. (2013). Do temporary agency workers affect workplace performance? Journal of Productivity Analysis, 39, 131–138.
Burton, W., Morrison, A., & Wertheimer, A. (2003). Pharmaceuticals and worker productivity loss: A critical review of the literature. Journal of Occupational and Environmental Medicine, 45, 610–621.
Capri, S., Ceci, A., Terranova, L., Merlo, F., & Mantovani, L. (2001). Guidelines for economic evaluations in Italy: Recommendations from the Italian group of pharmacoeconomic studies. http://www.ispor.org/PEguidelines/source/Italy%20PE%20guidelines_Italy.
College Voor Zorgverzekeringen (2006). Guidelines for pharmacoeconomic research. http://www.ispor.org/PEguidelines/source/HTAGuidelinesNLupdated2006.
DeLeire, T., & Manning, W. (2004). Labor market costs of illness: Prevalence matters. Health Economics, 13, 239–250.
Knies, S., Boonen, A., Candel, M., Evers, S., & Severens, J. (2013). Compensation mechanisms for lost productivity: A comparison between four European countries. Value in Health, 16, 740–744.
Koopmanschap, M., Rutten, F., van Ineveld, B., & van Roijen, L. (1995). The friction cost method for measuring indirect costs of disease. Journal of Health Economics, 14, 171–189.
Koopmanschap, M., & van Ineveld, B. (1992). Towards a new approach for estimating indirect cost of disease. Social Science and Medicine, 34, 1005–1010.
Krol, M., Brouwer, W., & Rutten, F. (2013). Productivity costs in economic evaluations: Past, present, future. Pharmacoeconomics, 31, 537–549.
Krol, M., Brouwer, W., Severens, J., Kaper, J., & Evers, S. (2012). Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects. Social Science and Medicine, 75, 1981–1988.
Leigh, J. P. (1981). The effects of union membership on absence from work due to illness. Journal of Labor Research, 2, 329–336.
Liljas, B. (1998). How to calculate indirect costs in economic evaluations. Pharmacoeconomics, 13, 1–17.
Loeppke, R., Hohn, T., Baase, C., Bunn, W., Burton, W., Eisenberg, B., et al. (2015). Integrating health and safety in the workplace: How closely aligning health and safety strategies can yield measurable benefits. Journal of Occupational and Environmental Medicine, 57, 585–597.
Pauly, M., Nicholson, S., Polsky, D., Berger, M., & Sharda, C. (2008). Valuing reductions in on-the-job illness: ‘Presenteeism’ from managerial and economic perspectives. Health Economics, 17, 469–485.
Pauly, M., Nicholson, S., Xu, P. D. J., Danzon, P., Murray, J., & Berger, M. (2002). A general model of the impact of absenteeism on employers and employees. Health Economics, 11, 221–231.
Pharmaceutical Benefits Advisory Committee (2008). Guidelines for preparing submissions to the pharmaceutical benefits advisory committee. http://www.ispor.org/PEguidelines/source/Australia-Guidelines-for-preparing-submissions-to-the-Pharmaceutical-Benefits-Advisory-Committee-2008.
Pharmaceutical Benefits Board (2003). General guidelines for economic evaluations from the pharmaceutical benefits board. http://www.ispor.org/PEguidelines/source/Guidelines_in_Sweden.
Suhrcke, M., Sauto Arce, R., McKee, M., & Rocco, L. (2012). Economic costs of ill health in the European region. In J. Figueras & M. McKee (Eds.), Health systems, health, wealth and societal well-being: Assessing the case for investing in health systems (European Observatory on Health Care Systems). New York: Mcgraw Hill.
Walter, W., & Zehetmayr, S. (2006). Guidelines on health economic evaluation:consensus paper. http://www.ispor.org/PEguidelines/source/Guidelines_Austria.
Acknowledgements
This paper was partially prepared when M. Jakubczyk was at The University of Iowa, Tippie College of Business, which was possible thanks to the Fulbright Senior Award 2015/2016. We would also like to thank R. Amir for useful comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Appendix
Appendix
Proof of Proposition 1
We first show how \(\text {MP}^E({\cdot })\) can be presented in a different form, more convenient for the present proof. We start with rewriting Eq. 4 and then modify it (notice we write it for \((L+1)\)-th worker here and change how the summation range is denoted)
where we use the fact that for \(i\in {\mathbf {N}}, 0<i<L, {L \atopwithdelims ()i}={L-1 \atopwithdelims ()i} + {L-1 \atopwithdelims ()i-1}\). Hence, \(\text {MP}^E(L+1)\) is a weighted average (with weights s and \(1-s\)) of \(\text {MP}^E(L)\) and a similarly calculated expression in which we take \(\text {MP}\)s moved one worker to the right. As \(\text {MP}({\cdot })\) is decreasing it must be that
as \(\ge \) holds for each term of the summation. \(\square \)
Proof of Proposition 2
The proof takes several steps. First, notice that \(\text {MP}^E(1)=(1-s)\text {MP}(1)\), and \(\text {MP}^E(2)=(1-s)\left( s\times \text {MP}(1)+(1-s)\times \text {MP}(2)\right) \). Then, if \(\text {MP}(2)\ge \text {MP}(1)\), then \(\text {MP}^E(2)\ge \text {MP}^E(1)\) for any s. Thus, if \(\text {MP}({\cdot })\) is increasing initially, so is \(\text {MP}^E({\cdot })\).
Notice, that if \(\text {MP}({\cdot })\) is decreasing after some point, then \(\text {MP}^E\) must also decrease at some point. Say, we calculate \(\text {MP}^E({\cdot })\) for some \(0\ll L_1\ll L_2\), where already \(L_1\) is much greater than the point where \(\text {MP}({\cdot })\) started to be decreasing. Increasing \(L_2\) results in \(\text {MP}^E(L_2\)) being calculated (as a weighted sum in Eq. 4) averaging lower values of \(\text {MP}({\cdot })\) than when calculating \(\text {MP}^E(L_1)\) (the weights assigned to the values of \(\text {MP}({\cdot })\) prevailing in both sums can be made arbitrarily small by increasing \(L_2\)).
We now show that if \(\text {MP}^E(L+1)<\text {MP}^E(L)\) then \(\text {MP}^E({\cdot })\) must be strictly decreasing further on. This is the main part of the whole proof, and again it is done in several steps. First, \(\text {MP}^E({\cdot })\) is calculated as an expected value of \(\text {MP}({\cdot })\) function calculated for a variable distributed according to a binomial distribution. It is then useful to see how the probabilities change in this distribution. Denote by B(k, n, p) the probability of k successes in n independent experiments, where a single success comes with probability p. We are interested in
and this is increasing in k.
As noticed in the proof of Proposition 1, \(\text {MP}^E(L+1)\) is calculated as a weighted average of \(\text {MP}^E(L)\) (calculated based on \(\text {MP}({\cdot })\) for workers from 1 to L) and a weighted average of \(\text {MP}\) calculated for workers from 2 to \((L+1)\) with weights given by a binomial distribution \(B({\cdot },L-1,1-s)\). It will be useful to show that if
and so \(\text {MP}^E(L+1)<\text {MP}^E(L)\), then also
Let \({\varDelta }(i)\) denote \(\text {MP}(i)-\text {MP}(i-1)\), defined for \(i\ge 2\). \({\varDelta }({\cdot })\) is positive for the part of \(\text {MP}({\cdot })\) with increasing marginal productivity. Our assumptions guarantee that \({\varDelta }({\cdot })\) changes from positive to negative. Rewriting inequality 10
and, analogously, in order to prove inequality 11 we need to show that
Obviously some \({\varDelta }({\cdot })\) values in inequality 12 must be negative. Assume non-trivially that also some (for \(i\le i^*\)) are positive. Then
where (I) is positive, and (II) is negative. We have \(\text {(I)}+\text {(II)}<0\), and so
as Eq. 9 is increasing in k, and so the negative elements in (II) are inflated more than the positive elements in (I). Rewriting the last inequality we get
which proves inequality 13. As the final step, notice that just as we decomposed \(\text {MP}^E(L+1)\), we can decompose \(\text {MP}^E(L+2)\):
where the inequality results from omitting a negative term and \(1-s^2\ge 1-s\). This finishes the proof of \(\text {MP}^E({\cdot })\) being decreasing ever since the first decrease.
Finally, to show that the first decrease will only happen for some L greater than the point at which \(\text {MP}({\cdot })\) attains its maximum, it’s enough to revert the argument presented in the proof of proposition 1. \(\square \)
Proof of Proposition 3
We will show that if for some L we have \(\text {MP}^E(L) \le \text {MP}^E(L+1) \ge \text {MP}^E(L+2)\), then the difference \(\text {MP}^E(L+2)-\text {MP}^E(L+1)\) is strictly increasing in s. Based on the decomposition presented in the proof of Proposition 1, this difference amounts to
and so to
or, more concisely, to \((1-s)^2\sum _{i=0}^L {L \atopwithdelims ()i}(1-s)^i s^{L-i}{\varDelta }(i+2)\).
The derivative of this expression with respect to s is given as \(\text {(I)}+\text {(II)}+\text {(III)}+\text {(IV)}+\text {(V)}\), where
Now, \(\text {(II)}+\text {(IV)}=(1-s)^2 L\sum _{i=0}^{L-1} {L-1 \atopwithdelims ()i}(1-s)^i s^{L-1-i}{\varDelta }(i+2)\), while \(\text {(III)}+\text {(V)}=-(1-s)^2 L\sum _{i=0}^{L-1} {L-1 \atopwithdelims ()i}(1-s)^i s^{L-1-i}{\varDelta }(i+3)\).
Notice (cf. Eq. 8 in the proof of Proposition 1) that
Accounting for our assumptions, that directly proves that \(\text {(II)}+\text {(IV)}\ge 0\) and \(\text {(I)}\ge 0\) (applying the formula to \(\text {MP}^E(L+2)-\text {MP}^E(L+1)\)).
We can also decompose \(\text {MP}^E(L+2)\) into three elements as shown in first three lines of Eq. 14 in the proof or Proposition 2. Again, accounting for the fact that \(\text {MP}^E(L) \le \text {MP}^E(L+1) \ge \text {MP}^E(L+2)\) it must be that \(\text {(III)}+\text {(V)}\ge 0\).
If either \(\text {MP}^E(L) < \text {MP}^E(L+1)\) or \(\text {MP}^E(L+1) > \text {MP}^E(L+2)\), then the derivative is strictly positive (for \(s<1\)). \(\square \)
Rights and permissions
About this article
Cite this article
Jakubczyk, M., Koń, B. The impact of firms’ adjustments on the indirect cost of illness. Int J Health Econ Manag. 17, 377–394 (2017). https://doi.org/10.1007/s10754-017-9212-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10754-017-9212-1